poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $130

Jul 23, 2026, 6:32 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $75 to $130.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LQDA
Source
benzinga
Observed
Jul 23, 2026, 6:32 PM
Checked
Jul 23, 2026, 6:32 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 6:22 PMNa

    Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

    Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.

    Read original at zacks-investment-research
    LQDAINSM
  2. Aug 14, 2026, 4:47 AMEric Volkman

    Why Liquidia Stock Was Diving This Week

    Liquidia's stock fell 20% week-to-date following its Q2 earnings report, despite beating revenue expectations ($171.7M vs. $171M consensus) and posting a $74.7M net profit. The decline was attributed to the stock's steep 155% year-to-date run-up creating unrealistic expectations. The company's pulmonary hypertension drug Yutrepia is performing well, though concerns remain about its reliance on a single molecule.

    Read original at the-motley-fool
    LQDA